Filtered By:
Source: American Heart Journal
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 491 results found since Jan 2013.
Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis
ConclusionThere is an incremental risk of ischemic stroke and MI from non-diabetics to non-insulin diabetics with the highest risk in insulin users. Protective effect of anticoagulation is attenuated with insulin use.
Source: American Heart Journal - May 11, 2019 Category: Cardiology Source Type: research
Outcomes of left Main revascularization in patients with acute coronary syndromes and stable ischemic heart disease: Analysis from the EXCEL trial
ConclusionsThe acuity of presentation did not predict outcomes in patients with LMCAD undergoing revascularization, nor did it discriminate patients who derive greater event-free survival from PCI versus CABG.
Source: American Heart Journal - May 4, 2019 Category: Cardiology Source Type: research
Smoking cessation and risk of recurrent cardiovascular events and mortality after a first manifestation of arterial disease
ConclusionsIrrespective of age at first CV event, cessation of smoking after a first CV event is related to a substantial lower risk of recurrent vascular events and all-cause mortality. Since smoking cessation is more effective in reducing CV risk than any pharmaceutical treatment of major risk factors, it should be a key objective for patients with vascular disease.
Source: American Heart Journal - April 25, 2019 Category: Cardiology Source Type: research
Ticagrelor in patients with Heart failure after acute coronary syndromes – Insights from the PLATelet inhibition and patient outcomes (PLATO) trial
ConclusionsIn patients with ACS, ticagrelor is more efficacious in protecting against new ischemic events and mortality than clopidogrel, irrespective of the presence of HF. There is no difference between ticagrelor or clopidogrel treatment in new-onset HF post-ACS.
Source: American Heart Journal - April 18, 2019 Category: Cardiology Source Type: research
Risk of obstructive coronary artery disease and major adverse cardiac events in patients with non-coronary atherosclerosis: Insights from the veterans affairs clinical assessment, reporting, and tracking (CART) program
ConclusionsIn patients undergoing coronary angiography, non-coronary atherosclerosis was associated with increased burden of oCAD and adverse events post PCI.
Source: American Heart Journal - April 16, 2019 Category: Cardiology Source Type: research
Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF
ConclusionGARFIELD-AF data highlights marked heterogeneity in stroke prevention strategies globally. Physicians are adopting an individualized approach to stroke prevention where NOACs are favored in patients with a lower stroke risk, but also in the elderly and patients with ACS.
Source: American Heart Journal - April 11, 2019 Category: Cardiology Source Type: research
Risk of stroke subsequent to infective endocarditis: A nationwide study
ConclusionPatients with non-surgically treated IE with a stroke during IE admission were at significant higher associated risk of subsequent stroke within the first year of follow-up as compared with patients without a stroke during IE admission. This risk difference was not evident beyond one year of discharge. These findings underline the need for identification of causes and mechanisms of recurrent strokes after IE to develop preventive means.
Source: American Heart Journal - March 28, 2019 Category: Cardiology Source Type: research
Rationale and design of the randomized, controlled early valve replacement guided by biomarkers of left ventricular decompensation in asymptomatic patients with severe aortic stenosis (EVOLVED) trial
ConclusionThe EVOLVED trial is the first multicenter randomized controlled trial to compare early aortic valve replacement to routine care in asymptomatic patients with severe aortic stenosis and mid-wall LGE.
Source: American Heart Journal - March 15, 2019 Category: Cardiology Source Type: research
Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design
ConclusionThis is the largest randomized trial to test if influenza vaccine compared to control reduces adverse vascular events in high risk individuals.Trial registration number:Clinicaltrials.govNCT02762851
Source: American Heart Journal - March 12, 2019 Category: Cardiology Source Type: research
Neck circumference and cardiovascular outcomes: Insights from the Jackson heart study
ConclusionsIn this large cohort of African American individuals, a larger NC was associated with increased risk for HF hospitalization following adjustment for age and sex, but this risk was not statistically significant after adjusting for other clinical variables. Although NC is not independently associated with increased risk for cardiovascular events, it may offer prognostic information particularly related to HF hospitalization.
Source: American Heart Journal - March 9, 2019 Category: Cardiology Source Type: research
Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design
ConclusionsThe TICO trial is an ongoing trial evaluating the efficacy and safety of ticagrelor monotherapy following 3-month DAPT exclusively in ACS patients treated with uniform BP-SES. It may provide novel insights regarding the need for adjusted use of DAPT for rebalancing risk–benefit in current practice and changing from the conventional concept of aspirin maintenance to a ticagrelor-based regimen in the management of ACS.
Source: American Heart Journal - March 9, 2019 Category: Cardiology Source Type: research
Rationale and design for AMPLATZER Amulet Left Atrial Appendage Occluder IDE randomized controlled trial (Amulet IDE Trial)
Publication date: May 2019Source: American Heart Journal, Volume 211Author(s): Dhanunjaya Lakkireddy, Stephan Windecker, David Thaler, Lars Søndergaard, John Carroll, Michael R Gold, Hongfei Guo, Kyle J Brunner, James B Hermiller, Hans-Christoph Diener, Boris Schmidt, Lee MacDonald, Moussa Mansour, Brijeshwar Maini, Joseph LevineAimsThe Amulet IDE Trial is an ongoing, prospective, randomized, multi-national trial, designed to evaluate the safety and effectiveness of the AMPLATZER Amulet Left Atrial Appendage Occluder for stroke prevention in comparison to the WATCHMAN Left Atrial Appendage Closure Device in patients with ...
Source: American Heart Journal - March 4, 2019 Category: Cardiology Source Type: research
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after PCI: An ancillary analysis from the RE-DUAL PCI trial
ConclusionDabigatran dual therapy reduced bleeding events irrespective of bleeding risk category and demonstrated similar efficacy regardless of stroke risk category when compared with warfarin triple therapy.
Source: American Heart Journal - March 4, 2019 Category: Cardiology Source Type: research
Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation
ConclusionsMorbidly obese AF patients treated with rivaroxaban had comparable risk of ischemic stroke/systemic embolism and major bleeding as those treated with warfarin, but lower healthcare resource utilization and costs.
Source: American Heart Journal - February 21, 2019 Category: Cardiology Source Type: research
Outcomes after STEMI in old multimorbid patients with complex health needs and the effect of invasive management
ConclusionsMultimorbid older people with complex health needs and STEMI had high rates of new ischemic events and death. In this cohort of older, high risk STEMI patients, an invasive strategy was associated with lower event rates. Randomized studies are needed to clarify whether these high risk patients who might benefit from invasive care are being managed too conservatively.
Source: American Heart Journal - February 1, 2019 Category: Cardiology Source Type: research
